Delayed Nyse  -  05/20 04:00:02 pm EDT
176.98 USD   +1.75%
05/20DOJ Objects to Cost of J&J Talc Unit Hiring Katyal For Appeal
05/20Top Midday Gainers
05/20Immix Biopharma Says Cancer Drug IMX-110 Showed Higher Survival Rate Versus Johnson & Johnson Unit's Trabectedin in Mice Study
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Prescription drugs, medical devices boost J&J in Q4

01/25/2022 | 11:05am EDT

Growing prescription drug and medical device sales nudged Johnson & Johnson past fourth-quarter earnings expectations, and the health care giant's COVID-19 vaccine gained momentum as well.

J&J's one-shot vaccine rang up $1.62 billion in sales in the last quarter of 2021, or more than double what it had recorded before the quarter, as drugstores and clinics started doling out booster shots.

The vaccine debuted last year and wound up bringing in $2.38 billion, or slightly less than what company leaders have said they expected. J&J said Tuesday that it forecasts vaccine sales of $3 billion to $3.5 billion this year too, as countries continue to fight variants of the coronavirus.

Much of J&J's vaccine sales came from outside the United States, where regulators said last month that most Americans should receive vaccines from Pfizer or Moderna instead of J&J’s version due to a rare blood clotting problem tied to the shot.

More than 16 million people in the U.S. have become fully vaccinated with the J&J shot, according to the Centers for Disease Control and Prevention. That compares to about 194 million who have used either the Pfizer or Moderna vaccines, which require two doses.

J&J has said it doesn't intend to profit from the vaccine.

Aside from growing vaccine sales, Johnson & Johnson also saw sales of its blood cancer treatment Darzalex jump 31% to about $1.65 billion.

Total sales from the company’s largest business, pharmaceuticals, jumped more than 16% to $14.29 billion in the quarter. Medical device sales also grew 4% to about $6.9 billion, even though the segment was still hurt by the ongoing pandemic, which has forced patients and hospitals to postpone surgeries and other care.

Johnson & Johnson said in November it will focus on those two segments by splitting off its consumer health business, which sells Band Aids and beauty products, into a separate, publicly traded company.

J&J has said it expects that separation to take place over the next couple years.

That segment brought in $3.66 billion in sales during the quarter.

Overall, the world’s biggest maker of health care products earned $4.74 billion in the fourth quarter, while sales grew 10% to $24.8 billion.

Research and development expenses also jumped 17% to $4.7 billion in the quarter.

Adjusted earnings totaled $2.13 per share, or a penny better than expected. Wall Street had expected revenue of $25.28 billion, according to FactSet.

In the full year, Johnson & Johnson earned $20.88 billion — a 42% increase from 2020 — as the company had more than a dozen prescription drugs top $1 billion in sales.

J&J also debuted a strong 2022 forecast of per-share earnings between $10.40 and $10.60. That's better than the $10.35 Wall Street had been projecting.

Shares of New Brunswick, New Jersey-based Johnson & Johnson, which is a component of the Dow Jones Industrial Average, climbed 1.7% to $165.70 in late morning trading Tuesday. The Dow and other broader indexes were down 1% or more.

Follow Tom Murphy on Twitter:

Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 1.75% 176.98 Delayed Quote.1.68%
MODERNA, INC. -4.97% 136.25 Delayed Quote.-46.35%
PFIZER, INC. 3.59% 52.47 Delayed Quote.-11.14%
All news about JOHNSON & JOHNSON
05/20DOJ Objects to Cost of J&J Talc Unit Hiring Katyal For Appeal
05/20Top Midday Gainers
05/20Immix Biopharma Says Cancer Drug IMX-110 Showed Higher Survival Rate Versus Johnson & J..
05/19The Janssen Pharmaceutical Companies - New Data Show TREMFYA (guselkumab) Binds to Both..
05/19New Janssen Campaign Developed by and for the LGBTQ+ Community Inspires Action and Empa..
05/18Thinking about trading options or stock in Costco, Dollar Tree, Micron, Upstart, or Joh..
05/17FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
05/17Citigroup Adjusts Price Target on Johnson & Johnson to $205 From $210, Reiterates Buy R..
05/16Mariners put RHP Steckenrider on restricted list, add Elías
05/13Idaho announces $119 million opioid crisis settlement
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 248 M - -
Net income 2022 23 016 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 19,9x
Yield 2022 2,52%
Capitalization 466 B 466 B -
EV / Sales 2022 4,75x
EV / Sales 2023 4,51x
Nbr of Employees 141 700
Free-Float 84,2%
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 176,98 $
Average target price 186,82 $
Spread / Average Target 5,56%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707
NOVO NORDISK A/S3.58%245 099